180 related articles for article (PubMed ID: 9395280)
1. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor.
Bischoff H; Angerbauer R; Bender J; Bischoff E; Faggiotto A; Petzinna D; Pfitzner J; Porter MC; Schmidt D; Thomas G
Atherosclerosis; 1997 Nov; 135(1):119-30. PubMed ID: 9395280
[TBL] [Abstract][Full Text] [Related]
2. Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition.
Bischoff H; Angerbauer R; Boberg M; Petzinna D; Schmidt D; Steinke W; Thomas G
Atherosclerosis; 1998 Sep; 139 Suppl 1():S7-13. PubMed ID: 9811153
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and clinical pharmacology of cerivastatin.
Bischoff H; Heller AH
Am J Cardiol; 1998 Aug; 82(4B):18J-25J. PubMed ID: 9737642
[TBL] [Abstract][Full Text] [Related]
4. Cerivastatin.
McClellan KJ; Wiseman LR; McTavish D
Drugs; 1998 Mar; 55(3):415-20; discussion 421-2. PubMed ID: 9530546
[TBL] [Abstract][Full Text] [Related]
5. Reduction of plasma cholesterol levels and induction of hepatic LDL receptor by cerivastatin sodium (CAS 143201-11-0, BAY w 6228), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in dogs.
Yasunobu Y; Hayashi K; Shingu T; Nomura K; Ohkura Y; Tanaka K; Kuga Y; Nomura S; Ohtani H; Nishimura T; Matsuura H; Kajiyama G
Cardiovasc Drugs Ther; 1997 Sep; 11(4):567-74. PubMed ID: 9358961
[TBL] [Abstract][Full Text] [Related]
6. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Plosker GL; Dunn CI; Figgitt DP
Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
[TBL] [Abstract][Full Text] [Related]
7. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor.
von Keutz E; Schlüter G
Am J Cardiol; 1998 Aug; 82(4B):11J-17J. PubMed ID: 9737641
[TBL] [Abstract][Full Text] [Related]
8. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD
J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors.
Parker RA; Clark RW; Sit SY; Lanier TL; Grosso RA; Wright JJ
J Lipid Res; 1990 Jul; 31(7):1271-82. PubMed ID: 2401858
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.
Davignon J; Hanefeld M; Nakaya N; Hunninghake DB; Insull W; Ose L
Am J Cardiol; 1998 Aug; 82(4B):32J-39J. PubMed ID: 9737644
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y
Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275
[TBL] [Abstract][Full Text] [Related]
12. RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
Amin D; Gustafson SK; Weinacht JM; Cornell SA; Neuenschwander K; Kosmider B; Scotese AC; Regan JR; Perrone MH
Pharmacology; 1993; 46(1):13-22. PubMed ID: 8434028
[TBL] [Abstract][Full Text] [Related]
13. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety.
Stein E
Am J Cardiol; 1998 Aug; 82(4B):40J-46J. PubMed ID: 9737645
[TBL] [Abstract][Full Text] [Related]
14. Bile acid derived HMG-CoA reductase inhibitors.
Kramer W; Wess G; Enhsen A; Bock K; Falk E; Hoffmann A; Neckermann G; Gantz D; Schulz S; Nickau L
Biochim Biophys Acta; 1994 Nov; 1227(3):137-54. PubMed ID: 7986821
[TBL] [Abstract][Full Text] [Related]
15. Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety.
Stein E
Atherosclerosis; 1998 Sep; 139 Suppl 1():S15-22. PubMed ID: 9811154
[TBL] [Abstract][Full Text] [Related]
16. Low-dose cerivastatin inhibits spontaneous atherogenesis in heterozygous watanabe hyper lipidemic rabbits.
Pauletto P; Puato M; Faggin E; Sartore S
J Vasc Res; 2000; 37(3):189-94. PubMed ID: 10859477
[TBL] [Abstract][Full Text] [Related]
17. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
[TBL] [Abstract][Full Text] [Related]
18. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
Stein EA
Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
[TBL] [Abstract][Full Text] [Related]
19. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.
Aikawa M; Rabkin E; Sugiyama S; Voglic SJ; Fukumoto Y; Furukawa Y; Shiomi M; Schoen FJ; Libby P
Circulation; 2001 Jan; 103(2):276-83. PubMed ID: 11208689
[TBL] [Abstract][Full Text] [Related]
20. Cerivastatin.
Cheng-Lai A
Heart Dis; 2000; 2(1):93-9. PubMed ID: 11728245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
